EQS-News: Douglas GmbH / Key word(s): Rating Douglas GmbH: Standard & Poor’s upgrades DOUGLAS‘ outlook to stable, affirms rating 06.07.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. IR NEWS Standard & Poor’s upgrades DOUGLAS‘ outlook to stable, affirms rating
Düsseldorf, 06.07.2023. Rating agency Standard & Poor’s Global Ratings has upgraded the outlook for DOUGLAS GmbH to stable as the operating performance exceeded its expectations in 2022, with record sales of €3.7 billion and stronger margins. Although S&P expects Douglas to sustain these improvements, the effect of inflation on discretionary spending and costs, combined with rising interest rates, could curtail further improvements. While S&P anticipates that results for the full fiscal year will be in line with trading in the first six months of fiscal 2023, the rating is still constrained by Douglas’ limited capacity to generate positive FOCF after leases, as well as the high leverage. With regard to the economic environment, S&P expects that discretionary spending could be hit by high inflation, but views beauty items as less discretionary. S&P anticipates that customers will cut back their consumption of larger articles, such as washing machines, and more discretionary items, such as clothing, rather than of their beauty products. ABOUT DOUGLAS DOUGLAS is Europe’s leading omni-channel beauty destination. We inspire customers to live their own kind of beauty by offering an unparalleled assortment in online stores, via a partner program and in around 1,800 stores. Strengthening our successful omni-channel positioning while consistently developing the customer experience is at the heart of our strategy. In its fiscal year 2021/22, DOUGLAS generated sales of 3.65 billion euros in perfume, decorative cosmetic, skin and hair care nutritional supplements, health care and accessories. CONTACTS DOUGLAS INVESTOR RELATIONS Stefanie Steiner Head of Investor Relations and M&A Phone: +49 (0) 211 16847 8594 Email: ir@douglas.de MEDIA RELATIONS Peter Wübben SVP Global Communications & Sustainability Phone: +49 (0) 211 16847 664 Email: pr@douglas.de 06.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Acesion wins €45m in Series B funding to develop atrial fibrillation therapy – Pharmaceutical Technology
AP31969 is an oral SK ion channel inhibitor that is being developed as a maintenance treatment to prevent the recurrence of atrial fibrillation. Image Credit: